David Geffen School of Medicine at UCLA

This is medical oncologist Dr. Neil Love.

At the 2026 Society of Gynecologic Oncology annual meeting on women's cancer in San Juan, Puerto Rico, we held a CME meeting moderated by Dr. Shannon Westin from the MD Anderson Cancer Center in Houston and faculty members Professor Nicoletta Colombo, from the European Institute of Oncology, IRCCS, in Milan, Italy, Dr. Alexander Olawaiya from the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania, and Dr. Gottfried Konechny from the David Geffen School of Medicine at UCLA in Los Angeles, California.

Included in the meeting were a series of pre-recorded video case presentations by Professor Jonathan Letterman from the UCL Cancer Institute in London, United Kingdom, Dr. Ursula Matalonis from the Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr. Angela Secord from the Duke Cancer Institute in Durham, North Carolina.

These cases were discussed by the faculty panel, beginning with a patient from Professor Letterman, a 70-year-old woman with a previous history in 2016 of surgery for stage 3 endometrioid high-grade carcinoma of the ovary.

This is medical oncologist Dr. Neil Love.

At the 2026 Society of Gynecologic Oncology annual meeting on women's cancer in San Juan, Puerto Rico, we held a CME meeting moderated by Dr. Shannon Westin from the MD Anderson Cancer Center in Houston and faculty members Professor Nicoletta Colombo and from the European Institute of Oncology IRCCS in Milan, Italy, Dr. Alexander Olawaiya from the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania, and Dr. Godfried Konechny from the David Geffen School of Medicine at UCLA in Los Angeles, California.

Included in the meeting were a series of prerecorded video case presentations by Professor Jonathan Letterman from the UCL Cancer Institute in London, United Kingdom, Dr. Ursula Matalonis from the Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr. Angela Secord from the Duke Cancer Institute in Durham, North Carolina.

These cases were discussed by the faculty panel, beginning with a patient from Professor Letterman, a 70-year-old woman with a previous history in 2016 of surgery for stage 3 endometrioid high-grade carcinoma of the ovary.

It seeks to provide respite for burnout among healthcare professionals and community organizers, all connected to the arts.

Dr. Bath is a Professor and Vice Chair for Justice, Equity, Diversity, and Inclusion in the Department of Psychiatry and Assistant Dean for Faculty Initiatives in the UCLA David Geffen School of Medicine, Office of Inclusive Excellence.

Born certified in child, adolescent, adult, and forensic psychiatry, she has a longstanding interest in community mental health and has committed her career to advancing health equity for ethno-racially minoritized and structurally marginalized youth and families.

Her special focus, youth impacted by the foster care and juvenile legal systems.

Well, I salute both of you in this incredibly ambitious and far-reaching work in the arts and health.

We've been speaking with Patrisse Cullors, inaugural visiting senior fellow and artist healer in residence for the HEARTS program, and that is health education through arts and research in thriving spaces at UCLA.

And the founder of this amazing program, Dr. Eraka Bath, psychiatrist and teacher and vice chair at the UCLA David Geffen School of Medicine.

Before I let you go, though, our final question on Behind the Curtain, traditionally, what's the song in your head these days?

This is medical oncologist Dr. Neil Love.

At the 2026 Society of Gynecologic Oncology annual meeting on women's cancer in San Juan, Puerto Rico, we held a CME meeting moderated by Dr. Shannon Westin from the MD Anderson Cancer Center in Houston and faculty members Professor Nicoletta Colombo and from the European Institute of Oncology IRCCS in Milan, Italy, Dr. Alexander Olawaiya from the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania, and Dr. Godfried Konechny from the David Geffen School of Medicine at UCLA in Los Angeles, California.

Included in the meeting were a series of prerecorded video case presentations by Professor Jonathan Letterman from the UCL Cancer Institute in London, United Kingdom, Dr. Ursula Matalonis from the Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr. Angela Secord from the Duke Cancer Institute in Durham, North Carolina.

These cases were discussed by the faculty panel, beginning with a patient from Professor Letterman, a 70-year-old woman with a previous history in 2016 of surgery for stage 3 endometrioid high-grade carcinoma of the ovary.

This is medical oncologist Dr. Neil Love.

At the 2026 Society of Gynecologic Oncology annual meeting on women's cancer in San Juan, Puerto Rico, we held a CME meeting moderated by Dr. Shannon Weston from the MD Anderson Cancer Center in Houston and faculty members Professor Nicoletta Colombo, from the European Institute of Oncology, IRCCS, in Milan, Italy, Dr. Alexander Olawaiye from the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania, and Dr. Gottfried Konechny from the David Geffen School of Medicine at UCLA in Los Angeles, California.

Included in the meeting were a series of pre-recorded video case presentations by Professor Jonathan Letterman from the UCL Cancer Institute in London, United Kingdom, Dr. Ursula Matalonis from the Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr. Angela Secord from the Duke Cancer Institute in Durham, North Carolina.

These cases were discussed by the faculty panel, beginning with a patient of Dr. Secord, a 69-year-old woman with a germline BRCA2 mutation who was status post multiple surgeries, intraperitoneal chemotherapy, but with further progression of platinum-resistant disease.

This is medical oncologist Dr. Neil Love.

At the 2026 Society of Gynecologic Oncology annual meeting on women's cancer in San Juan, Puerto Rico, we held a CME meeting moderated by Dr. Shannon Westin from the MD Anderson Cancer Center in Houston and faculty members Professor Nicoletta Colombo, from the European Institute of Oncology IRCCS in Milan, Italy, Dr. Alexander Olawaiye from the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania, and Dr. Gottfried Konechny from the David Geffen School of Medicine at UCLA in Los Angeles, California.

Included in the meeting were a series of pre-recorded video case presentations by Professor Jonathan Letterman from the UCL Cancer Institute in London, United Kingdom, Dr. Ursula Madelonis from the Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr. Angela Secord from the Duke Cancer Institute in Durham, North Carolina.

These cases were discussed by the faculty panel, beginning with a patient of Dr. Secord, a 69-year-old woman with a germline BRCA2 mutation who was status post multiple surgeries, intraperitoneal chemotherapy, but with further progression of platinum-resistant disease.

This is medical oncologist Dr. Neil Love.

At the 2026 Society of Gynecologic Oncology annual meeting on women's cancer in San Juan, Puerto Rico, we held a CME meeting moderated by Dr. Shannon Westin from the MD Anderson Cancer Center in Houston and faculty members Professor Nicoletta Colombo, from the European Institute of Oncology IRCCS in Milan, Italy, Dr. Alexander Olawaiye from the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania, and Dr. Gottfried Konecny from the David Geffen School of Medicine at UCLA in Los Angeles, California.

Included in the meeting were a series of pre-recorded video case presentations by Professor Jonathan Letterman from the UCL Cancer Institute in London, United Kingdom, Dr. Ursula Matalonis from the Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr. Angela Secord from the Duke Cancer Institute in Durham, North Carolina.

These cases were discussed by the faculty panel, beginning with a patient of Dr. Secord, a 69-year-old woman with a germline BRCA2 mutation who was status post multiple surgeries, intraperitoneal chemotherapy, but with further progression of platinum-resistant disease.